EP1537089A4 - Composes, compositions et procedes - Google Patents

Composes, compositions et procedes

Info

Publication number
EP1537089A4
EP1537089A4 EP03766028A EP03766028A EP1537089A4 EP 1537089 A4 EP1537089 A4 EP 1537089A4 EP 03766028 A EP03766028 A EP 03766028A EP 03766028 A EP03766028 A EP 03766028A EP 1537089 A4 EP1537089 A4 EP 1537089A4
Authority
EP
European Patent Office
Prior art keywords
methods
compounds compositions
compositions
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03766028A
Other languages
German (de)
English (en)
Other versions
EP1537089A2 (fr
Inventor
Gustave Bergnes
Whitney W Smith
Bing Yao
David J Morgans Jr
Andrew Mcdonald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytokinetics Inc
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of EP1537089A2 publication Critical patent/EP1537089A2/fr
Publication of EP1537089A4 publication Critical patent/EP1537089A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
EP03766028A 2002-07-23 2003-07-23 Composes, compositions et procedes Withdrawn EP1537089A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39822402P 2002-07-23 2002-07-23
US398224P 2002-07-23
PCT/US2003/023319 WO2004009036A2 (fr) 2002-07-23 2003-07-23 Composes, compositions et procedes

Publications (2)

Publication Number Publication Date
EP1537089A2 EP1537089A2 (fr) 2005-06-08
EP1537089A4 true EP1537089A4 (fr) 2008-04-16

Family

ID=30771199

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03766028A Withdrawn EP1537089A4 (fr) 2002-07-23 2003-07-23 Composes, compositions et procedes

Country Status (5)

Country Link
US (2) US7211580B2 (fr)
EP (1) EP1537089A4 (fr)
JP (1) JP2006501201A (fr)
AU (1) AU2003256805A1 (fr)
WO (1) WO2004009036A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7230000B1 (en) * 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
EP1480980A4 (fr) * 2002-02-15 2005-04-20 Cytokinetics Inc Syntheses de quinazolinones
AU2003223786A1 (en) * 2002-05-09 2003-11-11 Cytokinetics, Inc. Compounds, methods and compositions
US7214800B2 (en) * 2002-05-09 2007-05-08 Cytokinetics, Inc. Compounds, compositions, and methods
US7038048B2 (en) * 2002-05-23 2006-05-02 Cytokinetics, Inc. 3H-pyridopyrimidin-4-one compounds, compositions, and methods of their use
US7041676B2 (en) * 2002-06-14 2006-05-09 Cytokinetics, Inc. Compounds, compositions, and methods
AU2003256805A1 (en) * 2002-07-23 2004-02-09 Cytokinetics, Inc. Compounds compositions and methods
AU2003262747A1 (en) * 2002-08-21 2004-03-11 Cytokinetics, Inc. Compounds, compositions, and methods
EP1558083A4 (fr) * 2002-09-30 2008-04-16 Cytokinetics Inc Composes, compositions, et procedes
US20070149500A1 (en) * 2003-01-17 2007-06-28 Han-Jie Zhou Compounds, compositions, and methods
JP2007510660A (ja) * 2003-11-07 2007-04-26 サイトキネティクス・インコーポレーテッド 化合物、組成物及び方法
US7439254B2 (en) * 2003-12-08 2008-10-21 Cytokinetics, Inc. Compounds, compositions, and methods
US20080249112A1 (en) 2004-04-06 2008-10-09 Chiron Corporation Mitotic Kinesin Inhibitors
PL1753723T3 (pl) 2004-05-21 2009-01-30 Novartis Vaccines & Diagnostics Inc Podstawione pochodne chinoliny jako inhibitory kinezyn mitotycznych
AU2005258135B2 (en) 2004-06-18 2011-09-22 Novartis Vaccines And Diagnostics Inc. N- (1- (1-benzyl -4-phenyl-1H-imidazol-2-YL) -2,2-dymethylpropyl) benzamide derivatives and related compounds as kinesin spindle protein (KSP) inhibitors for the treatment of cancer
CA2575188A1 (fr) 2004-08-18 2006-02-23 Astrazeneca Ab Enantiomeres de pyrimidones fusionnes selectionnes et utilisations dans le traitement et la prevention du cancer
CN101233115A (zh) 2004-10-19 2008-07-30 诺华疫苗和诊断公司 吲哚和苯并咪唑衍生物
KR101129868B1 (ko) * 2006-10-04 2012-04-12 화이자 프로덕츠 인코포레이티드 칼슘 수용체 길항제로서의 피리도［4,3-ｄ］피리미딘-4(3Ｈ)-온 유도체
CA2668661A1 (fr) 2006-11-13 2008-05-29 Novartis Ag Composes de pyrazole et de triazole substitues comme inhibiteurs de ksp
EP2106399A2 (fr) 2007-01-05 2009-10-07 Novartis AG Dérivés d'imidazole en tant qu'inhibiteurs de la protéine de fuseau kinésine (eg5)
BRPI0813355A2 (pt) * 2007-06-22 2014-12-30 Arqule Inc Compostos de quinazolinona e métodos de uso dos mesmos
MY157495A (en) * 2007-09-26 2016-06-15 Celgene Corp 6-,7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
EP2638008B1 (fr) * 2010-11-10 2015-07-01 Actelion Pharmaceuticals Ltd Dérivés de lactame utiles en tant qu'antagonistes du récepteur de l'orexine
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001098278A1 (fr) * 2000-06-21 2001-12-27 Cytokinetics, Inc. Methodes et compositions d'utilisation des quinazolinones

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1249281B (fr) 1963-05-18
US3320124A (en) 1964-07-20 1967-05-16 American Cyanamid Co Method for treating coccidiosis with quinazolinones
BG16042A3 (bg) 1968-11-12 1972-05-20 Nans Ott Метод за получаване на нови 2(1н)-хиназолинони
US3962244A (en) 1971-01-23 1976-06-08 Hoechst Aktiengesellschaft Benzene sulfonyl ureas
US3740442A (en) 1972-01-14 1973-06-19 Sandoz Ag 2-isopropylaminobenzophenones in treating inflammation
US4011324A (en) 1976-01-20 1977-03-08 Pfizer Inc. Esters and amides of pyrimido[4,5-b]quinolin-4(3H)-one-2-carboxylic acids as antiulcer agents
US4281127A (en) 1979-07-09 1981-07-28 Hoffmann-La Roche Inc. Trans-3-(4-oxo-4H-quinazolin-3-yl)-2-propenoic acid derivatives
EP0278530A3 (fr) 1980-08-30 1989-08-02 Hoechst Aktiengesellschaft Dérivés amino-acides, leur procédé de préparation, les agents les contenant et leur emploi
GB8524663D0 (en) 1985-10-07 1985-11-13 Fujisawa Pharmaceutical Co Quinazoline derivatives
DE3609598A1 (de) 1986-03-21 1987-10-01 Hoechst Ag 2-azolylmethyl-2-aryl-1,3-dioxolane und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
US5187167A (en) 1986-03-27 1993-02-16 Imperial Chemical Industries Plc Pharmaceutical compositions comprising quinazolin-4-one derivatives
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
US4670560A (en) * 1986-04-28 1987-06-02 Ortho Pharmaceutical Corporation Thienopyrimidine-2,4-dione derivatives and intermediates thereof
US4729996A (en) 1986-05-29 1988-03-08 Harbor Branch Oceanographic Institution, Inc. Antitumor compositions and their methods of use
GB8707053D0 (en) 1987-03-25 1987-04-29 Ici Plc Anti-tumour agents
US4808590A (en) 1987-07-17 1989-02-28 Harbor Branch Oceanographic Institution, Inc. Antiviral, antitumor and antifungal compositions and their methods of use
US4866084A (en) 1987-07-17 1989-09-12 Harbor Branch Oceanographic Institution, Inc. Topsentin compounds effective against viruses and certain tumors
US5756450A (en) 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
US4857530A (en) 1987-11-03 1989-08-15 Warner-Lambert Company Substituted quinazolinones as anticancer agents
GB8827820D0 (en) 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
GB8827988D0 (en) 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
US4970226A (en) 1989-10-03 1990-11-13 Harbor Branch Oceanographic Institution, Inc. Bis-indole imidazole compounds which are useful antitumor and antimicrobial agents
US5264439A (en) 1990-02-13 1993-11-23 Merck & Co., Inc. Quinazolinone, triazolinone and pyrimidinone angiotensin II antagonists incorporating a substituted benzyl element
IL98167A0 (en) 1990-05-30 1992-06-21 Ici Plc Anti-tumour quinazoline derivatives,processes for their preparation and pharmaceutical compositions comprising them
FR2665159B1 (fr) 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
EP0481614A1 (fr) 1990-10-01 1992-04-22 Merck & Co. Inc. Pyridopyrimidinones substituées et hétérocyles apparantés comme antagonistes de la angiotensine II
GB9105771D0 (en) 1991-03-19 1991-05-01 Cancer Res Inst Royal Anti-cancer compounds
US5714493A (en) 1991-05-10 1998-02-03 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5316906A (en) 1991-08-23 1994-05-31 Molecular Probes, Inc. Enzymatic analysis using substrates that yield fluorescent precipitates
US5204354A (en) 1992-02-14 1993-04-20 Merck & Co., Inc. Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders
GB9205907D0 (en) 1992-03-18 1992-04-29 Cancer Res Inst Royal Anti-cancer compounds
US5430148A (en) 1992-03-31 1995-07-04 Agouron Pharmaceuticals, Inc. Antiproliferative quinazolines
US5817662A (en) 1992-11-09 1998-10-06 Cell Therapeutics, Inc. Substituted amino alkyl compounds
US5780476A (en) 1992-11-16 1998-07-14 Cell Therapeutics, Inc. Hydroxyl-containing xanthine compounds
AU6087894A (en) 1993-01-14 1994-08-15 Cell Therapeutics, Inc. Acetal or ketal substituted therapeutic compounds
WO1994016704A1 (fr) 1993-01-19 1994-08-04 Cell Therapeutics, Inc. Composes therapeutiques a substitution oxime
US5574057A (en) 1993-02-03 1996-11-12 University Of Utah Research Foundation Naamidine A extracted from sea sponges and methods for its use as an anti-tumor agent
US5837703A (en) 1993-03-31 1998-11-17 Cell Therapeutics, Inc. Amino-alcohol substituted cyclic compounds
US5342944A (en) 1993-07-19 1994-08-30 American Cyanamid Company Process for the preparation of 2-alkyl-3,5,6,7- or 8-substituted-4(3H)-quinazolinones
US20020198326A1 (en) * 1993-11-12 2002-12-26 Taizo Aoyama Polyolefin resin composition
CA2113229C (fr) 1994-01-11 1999-04-20 Mark Pines Compositions anti-fibreuses contenant de la quinazolinone et methodes d'utilisation correspondantes
AU1831395A (en) 1994-01-14 1995-08-01 Cell Therapeutics, Inc. Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf
WO1995022546A1 (fr) 1994-02-18 1995-08-24 Cell Therapeutics, Inc. Mediateurs de signalisation intracellulaire
WO1995024190A2 (fr) 1994-03-07 1995-09-14 Sugen, Inc. Inhibiteurs de tyrosine-kinase receptrice destines a inhiber les troubles lies a la proliferation cellulaire et compositions les contenant
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
US5807861A (en) 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
US5801182A (en) 1994-03-24 1998-09-01 Cell Therapeutics, Inc. Amine substituted compounds
US5756502A (en) 1994-08-08 1998-05-26 Warner-Lambert Company Quinazolinone derivatives as cholyecystokinin (CCK) ligands
JPH09165385A (ja) 1994-08-26 1997-06-24 Kyowa Hakko Kogyo Co Ltd キナゾリン誘導体
US5891879A (en) 1994-08-31 1999-04-06 Hadasit Medical Research Services & Development Co., Inc. Quinazolinone-containing pharmaceutical compositions and methods for the use thereof
US5753664A (en) 1995-03-16 1998-05-19 Takeda Chemical Industries, Ltd. Heterocyclic compounds, their production and use
US6245768B1 (en) 1995-06-05 2001-06-12 Neurogen Corporation 1-(N′-(arylalkylaminoalkyl)) aminoisoindoles; a new class of dopamine receptor subtype specific ligands
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
CN1090621C (zh) 1995-08-30 2002-09-11 株式会社大冢制药厂 制备喹唑啉－4－酮衍生物的方法
US5783577A (en) 1995-09-15 1998-07-21 Trega Biosciences, Inc. Synthesis of quinazolinone libraries and derivatives thereof
DE19546918A1 (de) 1995-12-15 1997-06-19 Bayer Ag Bicyclische Heterocyclen
DE19615262A1 (de) 1996-04-18 1997-10-23 Bayer Ag Heteroverknüpfte Phenylglycinolamide
WO1997043276A1 (fr) * 1996-05-15 1997-11-20 Pfizer Inc. Nouvelles 4(3h)-quinazolinones disubstituees en position 2,3
US6008010A (en) 1996-11-01 1999-12-28 University Of Pittsburgh Method and apparatus for holding cells
US5852024A (en) 1997-02-11 1998-12-22 Hadasit Treatment and prevention of adhesions
US5948775A (en) 1997-03-19 1999-09-07 American Home Products Corporation 2- or 3-(substitutedaminoalkoxyphenyl)quinazolin-4-ones
US6627755B1 (en) * 1997-06-09 2003-09-30 Pfizer Inc Quinazolin-4-one AMPA antagonists
US5939421A (en) 1997-07-01 1999-08-17 Signal Pharmaceuticals, Inc. Quinazoline analogs and related compounds and methods for treating inflammatory conditions
IL125950A0 (en) 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
EP1049475A4 (fr) 1998-01-08 2003-06-04 Univ California MODULATEURS DU MOTEUR DE KINESINE DERIVES DE L'EPONGE DE MER $i(ADOCIA)
US6214879B1 (en) * 1998-03-24 2001-04-10 Virginia Commonwealth University Allosteric inhibitors of pyruvate kinase
WO2001016114A2 (fr) * 1999-08-27 2001-03-08 Chemocentryx, Inc. Composes et techniques permettant de moduler la fonction du recepteur cxcr3
US6156758A (en) * 1999-09-08 2000-12-05 Isis Pharmaceuticals, Inc. Antibacterial quinazoline compounds
ES2234662T3 (es) 1999-09-16 2005-07-01 Curis, Inc. Mediadores de rutas de señalizacion hedgehog, composiciones y usos relacionados con los mismos.
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
US6495561B2 (en) 1999-10-29 2002-12-17 Merck & Co., Inc. 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists
US6380205B1 (en) 1999-10-29 2002-04-30 Merck & Co., Inc. 2-cyclohexyl quinazoline NMDA/NR2B antagonists
US6613798B1 (en) 2000-03-30 2003-09-02 Curis, Inc. Small organic molecule regulators of cell proliferation
US7115653B2 (en) * 2000-03-30 2006-10-03 Curis, Inc. Small organic molecule regulators of cell proliferation
ES2567260T3 (es) * 2000-04-25 2016-04-21 Icos Corporation Inhibidores de la fosfatidilinositol 3-quinasa delta humana
US20020165221A1 (en) 2000-10-13 2002-11-07 Baxter Anthony David Mediators of hedgehog signaling pathways, compositions and uses related thereto
AUPR201600A0 (en) * 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
NZ526622A (en) 2000-12-11 2006-07-28 Amgen Sf Llc CXCR3 antagonists
JP2004529918A (ja) 2001-04-09 2004-09-30 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド インテグリンに由来する疾患の治療のためのキナゾリンおよびキナゾリン類似化合物
US20030096813A1 (en) * 2001-04-20 2003-05-22 Jingrong Cao Compositions useful as inhibitors of GSK-3
US7365199B2 (en) 2001-04-20 2008-04-29 Fujifilm Corporation Dye-forming coupler, silver halide photographic light-sensitive material, and azomethine dye compound
US6794379B2 (en) 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
US6596723B1 (en) * 2001-07-16 2003-07-22 Essential Therapeutics, Inc. Fungal efflux pump inhibitors
US20030144350A1 (en) 2001-07-20 2003-07-31 Adipogenix, Inc. Fat accumulation-modulation compounds
CA2459584A1 (fr) 2001-09-05 2003-03-13 Cynthia C. Bamdad Compositions et methodes de traitement du cancer
ATE469648T1 (de) 2001-09-05 2010-06-15 Minerva Biotechnologies Corp Zusammensetzungen und deren verwendung zur behandlung von krebs
WO2003039460A2 (fr) * 2001-11-07 2003-05-15 Merck & Co., Inc. Inhibiteurs de la kinesine mitotique
AU2002366103A1 (en) 2001-11-19 2003-06-10 Iconix Pharmaceuticals, Inc. Modulators of rho c activity
US6753428B2 (en) 2001-11-20 2004-06-22 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
EP1480980A4 (fr) * 2002-02-15 2005-04-20 Cytokinetics Inc Syntheses de quinazolinones
US7074805B2 (en) 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US20030158188A1 (en) 2002-02-20 2003-08-21 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7214800B2 (en) * 2002-05-09 2007-05-08 Cytokinetics, Inc. Compounds, compositions, and methods
AU2003223786A1 (en) * 2002-05-09 2003-11-11 Cytokinetics, Inc. Compounds, methods and compositions
US7038048B2 (en) * 2002-05-23 2006-05-02 Cytokinetics, Inc. 3H-pyridopyrimidin-4-one compounds, compositions, and methods of their use
US7041676B2 (en) * 2002-06-14 2006-05-09 Cytokinetics, Inc. Compounds, compositions, and methods
US20040092561A1 (en) * 2002-11-07 2004-05-13 Thomas Ruckle Azolidinone-vinyl fused -benzene derivatives
AU2003256805A1 (en) * 2002-07-23 2004-02-09 Cytokinetics, Inc. Compounds compositions and methods
AU2003262747A1 (en) * 2002-08-21 2004-03-11 Cytokinetics, Inc. Compounds, compositions, and methods
JP4977837B2 (ja) * 2003-09-10 2012-07-18 アイカジェン， インコーポレイテッド カリウム・チャネル・モジュレーターとしての縮合環式複素環
US20050152940A1 (en) * 2003-12-23 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001098278A1 (fr) * 2000-06-21 2001-12-27 Cytokinetics, Inc. Methodes et compositions d'utilisation des quinazolinones

Also Published As

Publication number Publication date
JP2006501201A (ja) 2006-01-12
AU2003256805A8 (en) 2004-02-09
WO2004009036A2 (fr) 2004-01-29
EP1537089A2 (fr) 2005-06-08
US7211580B2 (en) 2007-05-01
WO2004009036A3 (fr) 2004-08-19
US20080021050A1 (en) 2008-01-24
US20040142949A1 (en) 2004-07-22
AU2003256805A1 (en) 2004-02-09

Similar Documents

Publication Publication Date Title
AU2003262747A8 (en) Compounds, compositions, and methods
EP1503993A4 (fr) Composes, compositions et procedes
AU2003236527A8 (en) Compounds, compositions, and methods
AU2003265242A8 (en) Compounds, compositions, and methods
HK1070656A1 (en) Compounds, compositions, and methods
AU2003270015A8 (en) Compounds, compositions, and methods
GB0213638D0 (en) Composition
GB0411940D0 (en) Methods and compositions
EP1701725A4 (fr) Methodes et compositions
IL166331A0 (en) 5-arylterazole compounds compositions thereof and uses therefor
AU2003256805A8 (en) Compounds compositions and methods
AU2003299612A8 (en) Compounds, compositions and methods
IL167936A0 (en) Compounds, compositions,and methods
GB0203421D0 (en) Composition
AU2003290507A8 (en) Compounds, compositions and methods
GB0208608D0 (en) Composition
AU2003277079A8 (en) Compounds, compositions, and methods
GB0203280D0 (en) Anti-glycolytic composition
GB0211924D0 (en) Composition
AU2003300031A8 (en) Compounds, compositions, and methods
AU2003267169A8 (en) Compounds, compositions and methods
EP1495751A4 (fr) Composition de colorant capillaire
GB0211949D0 (en) Novel compounds compositions and processes
GB0213767D0 (en) Composition
GB0203616D0 (en) Composition

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050201

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

A4 Supplementary search report drawn up and despatched

Effective date: 20080317

17Q First examination report despatched

Effective date: 20081215

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090428